Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.

Autor: Jutzi JS; Section of Molecular Hematology, Department of Medicine I, Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Basu T; Section of Molecular Hematology, Department of Medicine I, Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Pellmann M; Section of Molecular Hematology, Department of Medicine I, Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Kaiser S; Section of Molecular Hematology, Department of Medicine I, Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Steinemann D; Department of Human Genetics, Hannover Medical School, Hannover, Germany., Sanders MA; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Hinai ASA; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Zeilemaker A; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Bojtine Kovacs S; Section of Molecular Hematology, Department of Medicine I, Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Koellerer C; Section of Molecular Hematology, Department of Medicine I, Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Ostendorp J; Section of Molecular Hematology, Department of Medicine I, Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Aumann K; Institute for Surgical Pathology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Wang W; Section of Molecular Hematology, Department of Medicine I, Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Raffoux E; Hôpital Saint-Louis, Paris 7 University, Service d'Hématologie Adulte, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France., Cassinat B; APHP, Hôpital Saint-Louis, Laboratoire de Biologie Cellulaire, Paris, France., Bullinger L; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany; and.; Department of Hematology, Oncology and Tumor Immunology, Charité-University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany., Schlegelberger B; Department of Human Genetics, Hannover Medical School, Hannover, Germany., Valk PJM; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Pahl HL; Section of Molecular Hematology, Department of Medicine I, Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Publikováno v: Blood [Blood] 2019 Apr 18; Vol. 133 (16), pp. 1766-1777. Date of Electronic Publication: 2019 Feb 12.